SCHEMBL51355

SCHEMBL51355

COc1ccc(CNC(C)(C)CO)cc1

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.58
ALDH1A1 P00352 3/20 0.51
PKM P14618 1/20 0.51
CYP2D6 P10635 1/20 0.50
MEN1 O00255 2/20 0.48
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
KMT2A Q03164 2/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
EPHX2 P34913 1/20 0.48
NR1H4 Q96RI1 1/20 0.48
CHRM2 P08172 1/20 0.46
GAA P10253 3/20 0.45
CALM1 P0DP23 1/20 0.44
MAPK1 P28482 1/20 0.44
MAPT P10636 1/20 0.44
CASR P41180 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21058229 0.84 ALDH1A1 (0.49) HTTALDH1A1PKMMEN1NPC1
SCHEMBL9595371 0.83 SMN1; SMN2 (0.53) HTTALDH1A1KMT2ACALM1MAPT
SCHEMBL13561014 0.82 ALDH1A1 (0.47) HTTALDH1A1PKMMEN1NPC1
SCHEMBL10245176 0.81 ALDH1A1 (0.53) HTTALDH1A1PKMMEN1NPC1
SCHEMBL21790569 0.81 ALDH1A1 (0.46) HTTALDH1A1PKMMEN1NPC1
SCHEMBL5516663 0.78 CASR (0.58) HTTALDH1A1CYP2D6MEN1NPC1
SCHEMBL15116693 0.77 NPC1 (0.54) HTTALDH1A1PKMMEN1NPC1
SCHEMBL3631502 0.77 HTT (0.61) HTTALDH1A1CYP2D6MEN1RAB9A
SCHEMBL22641815 0.76 ALDH1A1 (0.53) HTTALDH1A1PKMMEN1NPC1
SCHEMBL15125214 0.76 NPC1 (0.52) HTTALDH1A1PKMMEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2280981-B1 BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-04-23 EP disclosed
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
EP-2280981-A1 BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS Bristol-Myers Squibb Company (US) 2011-02-09 EP disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed
WO-2009117540-A1 BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-24 WO disclosed
WO-2009117540-A1 BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253677-A1 HIV Integrase Inhibitors DNTT, POLB, UNG HTT 4616/4885ALDH1A1 539/4885PKM 2659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.